Post-Transplant Maintenance Treatment Options in Multiple Myeloma

Maintenance treatment in multiple myeloma.

Maintenance chemotherapy has failed to demonstrate any benefit [1, 2]. Corticosteroid maintenance was found to prolong the duration of response; however, the effect on survival was controversial [3, 4]. Interferon-a represented a great hope in the 1980s but metaanalysis of randomized trials showed a modest increase in progression-free survival (PFS) and a minimal benefit in overall survival (OS...

Treatment of Multiple Myeloma

Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue.  La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours. 

Multiple myeloma: increasing our treatment options.

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma

Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). However, majority of patients eventually relapse, with a median PFS of around 36 months. Relapses are harder to treat and prognosis declines wit...

Maintenance therapy in multiple myeloma

The treatment of multiple myeloma (MM) has changed dramatically in the past twenty years with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT) in younger patients and, more recently, of three novel agents (thalidomide, bortezomib, and lenalidomide). When conventional chemotherapy was the only available possibility, complete responses (CR) were very rare and...